Equillium, Inc.

Today we announced that an abstract was accepted for poster presentation at the 39th?Annual Meeting of the Society for Immunotherapy of Cancer (SITC). Title:?Interleukin (IL)-15 and IL-21 synergistically enhance NK and CD8+ T cell responses Presenting Author:?Phoi Tiet, Senior Research Associate, Equillium, Inc. Abstract Number: 908 Location:?Exhibit Halls A & B Date:?Saturday, November 9, 2024 The abstract highlights that cytokines are a focus of anti-cancer therapeutic development due to their central role in regulating anti-tumoral immune responses, and that data demonstrates that IL-15 and IL-21 synergistically augment NK and CD8 T cells activities, which further enhanced their proliferation and cytolytic function. With the ability to rescue T cell dysfunction, this cytokine combination could be a promising treatment approach to stimulating anti-tumor immune responses.

Reminder...Get out and walk to end Lupus! https://walktoendlupus.org

Help us #WalktoEndLupusNow. Gather your friends, raise some $ and earn the exclusive Walk t-shirt when you hit $100! Register today at https://walktoendlupus.org

Join us on September 28 as we #WalkForAlopecia to help raise money for @NAAF_org https://www.naaf.org/walk/

It's conference season again! Equillium, Inc. presenting tomorrow, Tuesday, September 10th at 8:00 am ET at the H.C. Wainwright & Co., LLC Investor Conference. CEO, Bruce Steel, will provide an update on the full pipeline and milestones, including itolizumab and our Ono Pharmaceutical partnership. Live webcast and replay available on EQs events page: https://lnkd.in/gsAejSiJ

Equillium CEO, Bruce Steel, presenting today at 4:30 pm ET at the 2024 Wells Fargo Healthcare Conference in Boston. Presentation will provide an overview of the EQ's multi-cytokine inhibitor programs and platform, currently focused on dermatological and gastrointestinal indications, as well as the ongoing development of itolizumab in partnership with Ono Pharmaceutical and Ono’s pending option exercise decision to potentially acquire Equillium’s rights to itolizumab. https://lnkd.in/gsAejSiJ

Please join us in welcoming our newest Clinical Operations Team member, Annie Huynh.?She joins us as a Clinical Trial Manger and will be supporting the EQUATOR program for acute Graft-Versus-Host Disease.? ? Annie previously worked as a Sr. Project Manager in both Project Management and Clinical Operations at Nitto BioPharma and as a coordinator at UCSD Health. ? In her spare time, Annie enjoys Pilates, cycling and catching the occasional halibut under the Coronado Bridge. ? Welcome Annie!

"At Equillium, our community matters!" Thank you Life Science Cares San Diego and Feeding San Diego for your partnership! #LifeScienceCaresSanDiego #FeedingSanDiego #CommunityDay #SocialResponsibility #FunWellnessDay

As we enter the weekend, we want to welcome our newest team member, Hareth Yousef. Hareth joins the Clinical Operations Team as a Clinical Trial Associate. He will be supporting the EQUATOR program and the EQ101 program in alopecia areata.?

Today we announced positive topline data from our Phase 2, single dose, proof-of-concept (PoC) study of EQ101 in adult patients with moderate, severe or very-severe alopecia areata, an autoimmune disease driven by an immune cell attack of the hair follicles that causes hair loss. Results from the study demonstrated a favorable safety and tolerability profile with no serious adverse events and improvements in SALT scores above historically low placebo response rates. Of all subjects (baseline SALT of 35 - 100) that completed 24 weeks of treatment, 20% achieved a SALT score of less than 20 by week 24. Of those subjects with moderate to severe alopecia areata (SALT score 35 - 95) at baseline that completed 24 weeks of treatment, 29% achieved a SALT score of less than 20 by week 24, and a mean SALT improvement from baseline of 18%.? ? Equillium Announces Positive Topline Data from Phase 2 Study of EQ101 in Alopecia Areata ·????20% of all subjects that completed 24-week treatment period achieved SALT ≤ 20 ·????29% of completed subjects with moderate to severe disease (baseline SALT 35 to <95) achieved SALT ≤ 20 ·????EQ101 was well tolerated in subjects with alopecia areata with no serious adverse events reported ·????Data supports advancing EQ101 development in alopecia areata to include dose and delivery optimization ·????Data provides further support for opportunistic expansion in other dermatological conditions where IL-2, IL-9 and IL-15 inhibition is important such as vitiligo and atopic dermatitis https://lnkd.in/gqVvyqNb